Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 21:24:23 GMT -5
reread.. I am 100% positive that the flat lines on the CGM on twitter made most of the diabetics try out Afrezza and stick to afrezza.. some of them out of the way to change doctors to get prescriptions and some doctors finally got it... there is no way by reading the label and bound by label , I would try/prescribe afrezza and the social media would bias me towards afrezza Your experience with doctors is 180 degrees from my own. Most doctors I've interacted with give very little weight to the "I found this on the internet" patient input... very little weight to active hostility. I'm sure there are some exceptions but it is quite a leap to think that most of the obviously very few prescribing doctors were convinced by patients rather than being convinced by education sessions or simply by professional networking with the doctors that we know supported Afrezza even before it hit the market such as Edelman, Bode, etc. i am talking about patients /social media - and our discussion was about that..I was generalizing you get the idea...its a patient pull (mostly).. yes there are docs that are on board too..Not all of them.....just as patients... I dont want to discuss absolute numbers on doctors/patients becos we dont know ...and we are swaying away.. The point was most of the rx was from Social media and even SNY was visiting docs that prescribed Afrezza and who they didnt even sell to ( read that some where ) |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 21:24:27 GMT -5
Tier 2 with low pricing for out of pocket paying patients ( domestic and international ) - international being like Matt from Australia and Brendan from UK -individual buyers will alone cross 60k by a mile Big question is whether SNY has done ANYTHING with regard to international approvals... likely not. Are MNKD's remaining precious resources wisely spent on chasing after approval overseas, or better spent trying to turn on revenue in U.S.? If SNY had at least been in discussions with other regulators there might be some info to make a wise decision... such as likelihood of better label with existing data. But alas, I fear that SNY did nothing and we are flying blind... or rather MNKD is flying blind... obviously we investors have been blind, deaf and dumb for a long time. This is a very good point. Did you read the Tweet from today from the T1 diabetic? He is afraid of losing Afrezza because of how much easier it is to manage diabetes and to tell him where to March and he will go. That message is so powerful. If these results are real there is no reason this should not gain traction in the US. I agree that with these results they have to make an impact here. I am really starting to wonder if they are real because how can people say things like this and the drug fail? It does not make any logical sense. |
|
|
|
Post by dreamboatcruise on Jan 6, 2016 21:31:34 GMT -5
Big question is whether SNY has done ANYTHING with regard to international approvals... likely not. Are MNKD's remaining precious resources wisely spent on chasing after approval overseas, or better spent trying to turn on revenue in U.S.? If SNY had at least been in discussions with other regulators there might be some info to make a wise decision... such as likelihood of better label with existing data. But alas, I fear that SNY did nothing and we are flying blind... or rather MNKD is flying blind... obviously we investors have been blind, deaf and dumb for a long time. This is a very good point. Did you read the Tweet from today from the T1 diabetic? He is afraid of losing Afrezza because of how much easier it is to manage diabetes and to tell him where to March and he will go. That message is so powerful. If these results are real there is no reason this should not gain traction in the US. I agree that with these results they have to make an impact here. I am really starting to wonder if they are real because how can people say things like this and the drug fail? It does not make any logical sense. Surely you realize that our medical system treats many, many people in ways that are far from what would be best. |
|
|
|
Post by ricguy on Jan 6, 2016 21:32:37 GMT -5
Big question is whether SNY has done ANYTHING with regard to international approvals... likely not. Are MNKD's remaining precious resources wisely spent on chasing after approval overseas, or better spent trying to turn on revenue in U.S.? If SNY had at least been in discussions with other regulators there might be some info to make a wise decision... such as likelihood of better label with existing data. But alas, I fear that SNY did nothing and we are flying blind... or rather MNKD is flying blind... obviously we investors have been blind, deaf and dumb for a long time. This is a very good point. Did you read the Tweet from today from the T1 diabetic? He is afraid of losing Afrezza because of how much easier it is to manage diabetes and to tell him where to March and he will go. That message is so powerful. If these results are real there is no reason this should not gain traction in the US. I agree that with these results they have to make an impact here. I am really starting to wonder if they are real because how can people say things like this and the drug fail? It does not make any logical sense. The results are real. The thing is it is going to take a lot more people to sell to than the wonderful results we are seeing from what might seem like a lot of people but really isn't when you look the big picture. The script #s were not that great, maybe good for not really being promoted but not that great overall. SNY just didn't get it in enough people's hands for whatever reason, period. Seems so long ago when we were talking samples and how well they were doing and giving out more samples than expected. The one positive we can take from this is MNKD was dead if SNY kept stringing them along. At least now they have a fighting chance. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 21:34:59 GMT -5
This is a very good point. Did you read the Tweet from today from the T1 diabetic? He is afraid of losing Afrezza because of how much easier it is to manage diabetes and to tell him where to March and he will go. That message is so powerful. If these results are real there is no reason this should not gain traction in the US. I agree that with these results they have to make an impact here. I am really starting to wonder if they are real because how can people say things like this and the drug fail? It does not make any logical sense. Surely you realize that our medical system treats many, many people in ways that are far from what would be best. I have no faith in anything. I think everything is corrupt. I guess I am in denial because my money is involved. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 21:41:56 GMT -5
This is a very good point. Did you read the Tweet from today from the T1 diabetic? He is afraid of losing Afrezza because of how much easier it is to manage diabetes and to tell him where to March and he will go. That message is so powerful. If these results are real there is no reason this should not gain traction in the US. I agree that with these results they have to make an impact here. I am really starting to wonder if they are real because how can people say things like this and the drug fail? It does not make any logical sense. The results are real. The thing is it is going to take a lot more people to sell to than the wonderful results we are seeing from what might seem like a lot of people but really isn't when you look the big picture. The script #s were not that great, maybe good for not really being promoted but not that great overall. SNY just didn't get it in enough people's hands for whatever reason, period. Seems so long ago when we were talking samples and how well they were doing and giving out more samples than expected. The one positive we can take from this is MNKD was dead if SNY kept stringing them along. At least now they have a fighting chance. No I agree totally the amount of people is nothing. Its like the same 20-30 people I work in sales and every sale I close I send a questionnaire to ask my clients how I did. I ask for areas I can improve on. What stages they found difficult so I could shorten the transaction . MNKD should start sending questionnaires to diabetics that are currently on Afrezza (I have no idea if this data is attainable or even legal to do). They should ask how they were introduced to Afrezza, did insurance give them issues, were their Dr's resistant. They need to use that data. |
|
|
|
Post by dreamboatcruise on Jan 6, 2016 22:16:53 GMT -5
The results are real. The thing is it is going to take a lot more people to sell to than the wonderful results we are seeing from what might seem like a lot of people but really isn't when you look the big picture. The script #s were not that great, maybe good for not really being promoted but not that great overall. SNY just didn't get it in enough people's hands for whatever reason, period. Seems so long ago when we were talking samples and how well they were doing and giving out more samples than expected. The one positive we can take from this is MNKD was dead if SNY kept stringing them along. At least now they have a fighting chance. No I agree totally the amount of people is nothing. Its like the same 20-30 people I work in sales and every sale I close I send a questionnaire to ask my clients how I did. I ask for areas I can improve on. What stages they found difficult so I could shorten the transaction . MNKD should start sending questionnaires to diabetics that are currently on Afrezza (I have no idea if this data is attainable or even legal to do). They should ask how they were introduced to Afrezza, did insurance give them issues, were their Dr's resistant. They need to use that data. That is one reason they have a $0 copay for first month discount card and a coach program... to get the contact info for patients. One would assume that SNY would have to turn this list over to MNKD. |
|
|
|
Post by jpg on Jan 6, 2016 22:36:59 GMT -5
How would Mannkind pay for the safety study if it goes at it alone?
|
|
|
|
Post by mnkdnewb on Jan 6, 2016 23:07:28 GMT -5
My concern/fear/question with this would be why didn't MNKD go it alone in the first place and not even bother with a slimy French partner? They wanted/needed a partner for a reason and were in much better shape financial back then. IMHO because their business model is technosphere - not sales unless they would be forced to. |
|
|
|
Post by ricguy on Jan 6, 2016 23:37:19 GMT -5
My concern/fear/question with this would be why didn't MNKD go it alone in the first place and not even bother with a slimy French partner? They wanted/needed a partner for a reason and were in much better shape financial back then. IMHO because their business model is technosphere - not sales unless they would be forced to. Yep and I don't believe they would be successful trying out a new business model with the current state of affairs. If they were better off financially maybe they could learn as they go but they can't afford any more mistakes, they might have cashed in all their mistakes already, they need expertise going forward, they are on borrowed time right now. Not saying that they couldn't sell more than SNY, heck the kids selling lemonade could have done a better job than SNY but financially I'm concerned. Personally I believe they would sell Afrezza off to a co. before trying to sell it themselves but what the heck do I know when it comes to this co, every time I think I know what is coming we get another freaking surprise. I just want a beautiful cover girl jumping out of the cake this time instead of Costanza. |
|
